NO20063448L - Behandling av aromatase inhibitor terapi relatert-osteoporose - Google Patents

Behandling av aromatase inhibitor terapi relatert-osteoporose

Info

Publication number
NO20063448L
NO20063448L NO20063448A NO20063448A NO20063448L NO 20063448 L NO20063448 L NO 20063448L NO 20063448 A NO20063448 A NO 20063448A NO 20063448 A NO20063448 A NO 20063448A NO 20063448 L NO20063448 L NO 20063448L
Authority
NO
Norway
Prior art keywords
treatment
aromatase inhibitor
inhibitor therapy
related osteoporosis
osteoporosis
Prior art date
Application number
NO20063448A
Other languages
English (en)
Inventor
Philip Frost
Pol Boudes
Simon N Jenkins
Matthew L Sherman
Barry S Komm
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20063448L publication Critical patent/NO20063448L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

Det beskrives anvendelse av bazedoksifen (1-[4-(2-azepan-1-yl-etoksy)benzyl]-2-(4-hydroksy-fenyl)-3-metyl-1 H-indol-5-ol) ved behandling eller hemming av osteoporose og osteopeni knyttet til aromataseinhibitorterapi.
NO20063448A 2004-01-13 2006-07-26 Behandling av aromatase inhibitor terapi relatert-osteoporose NO20063448L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53603504P 2004-01-13 2004-01-13
PCT/US2005/000803 WO2005070434A2 (en) 2004-01-13 2005-01-11 Treatment of aromatase inhibitor therapy-related osteoporosis

Publications (1)

Publication Number Publication Date
NO20063448L true NO20063448L (no) 2006-09-29

Family

ID=34806981

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063448A NO20063448L (no) 2004-01-13 2006-07-26 Behandling av aromatase inhibitor terapi relatert-osteoporose

Country Status (19)

Country Link
US (1) US20050272717A1 (no)
EP (1) EP1703910A2 (no)
JP (1) JP2007517899A (no)
KR (1) KR20060127875A (no)
CN (1) CN1929835A (no)
AR (1) AR048394A1 (no)
AU (1) AU2005206137A1 (no)
BR (1) BRPI0506774A (no)
CA (1) CA2552725A1 (no)
CR (1) CR8495A (no)
EC (1) ECSP066699A (no)
IL (1) IL176628A0 (no)
NO (1) NO20063448L (no)
PA (1) PA8621401A1 (no)
RU (1) RU2006123939A (no)
SG (1) SG149081A1 (no)
TW (1) TW200526206A (no)
UA (1) UA84046C2 (no)
WO (1) WO2005070434A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114702A2 (en) * 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
AU2012275036B2 (en) * 2005-08-24 2016-05-19 Wyeth Llc Bazedoxifene acetate formulations and manufacturing process thereof
CN101304731B (zh) * 2005-08-24 2012-06-20 惠氏公司 醋酸苯卓昔芬制剂及其生产方法
WO2007045027A1 (en) 2005-10-19 2007-04-26 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
WO2013182169A1 (en) * 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
CN103860496A (zh) * 2014-03-14 2014-06-18 王志刚 一种醋酸巴多昔芬分散片及其制备方法
US20160051565A1 (en) * 2014-08-20 2016-02-25 Professional Compounding Centers Of America (Pcca) Transdermal Pharmaceutical Compositions Including Testosterone and an Aromatase Inhibitor
US9351977B2 (en) 2014-10-22 2016-05-31 Chavah Pty Ltd. Methods of reducing mammographic breast density and/or breast cancer risk
CN104546794A (zh) * 2015-01-05 2015-04-29 万特制药(海南)有限公司 一种醋酸巴多昔芬胶囊及其制备方法
SG11201803260PA (en) 2015-10-22 2018-05-30 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
AU2020287392A1 (en) 2019-06-03 2021-12-23 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW303299B (no) * 1993-07-22 1997-04-21 Lilly Co Eli
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6583170B1 (en) * 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
US20040192598A1 (en) * 2000-10-11 2004-09-30 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
CA2489098A1 (en) * 2002-06-13 2003-12-24 Wyeth Bazedoxifene treatment regimens

Also Published As

Publication number Publication date
SG149081A1 (en) 2009-01-29
CN1929835A (zh) 2007-03-14
CR8495A (es) 2007-03-06
EP1703910A2 (en) 2006-09-27
RU2006123939A (ru) 2008-02-20
JP2007517899A (ja) 2007-07-05
US20050272717A1 (en) 2005-12-08
CA2552725A1 (en) 2005-08-04
BRPI0506774A (pt) 2007-05-22
TW200526206A (en) 2005-08-16
AU2005206137A1 (en) 2005-08-04
WO2005070434A3 (en) 2006-06-08
AR048394A1 (es) 2006-04-26
IL176628A0 (en) 2006-10-31
UA84046C2 (ru) 2008-09-10
PA8621401A1 (es) 2006-07-03
ECSP066699A (es) 2006-10-31
WO2005070434A2 (en) 2005-08-04
KR20060127875A (ko) 2006-12-13

Similar Documents

Publication Publication Date Title
NO20063448L (no) Behandling av aromatase inhibitor terapi relatert-osteoporose
AR058892A1 (es) Metodos para tratar lupus cutaneo con el uso de compuestos de aminoisoindolina
BRPI0513866A (pt) composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação
NO20054369L (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
DK1755676T3 (da) Fotodynamisk terapi til behandling af hyperaktive talgkirtellidelser under anvendelse af påført verteporfin og/eller lemuteporfin
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
NO20060030L (no) Kombinasjonsterapi for b-cellelidelser
IL180147A0 (en) N - (1 - (1 - benzyl - 4 - phenyl - 1h-imidazol - 2 - yl) - 2,2 - dymethylpropyl) benzamide derivatives and related compounds as kinesin spidle protein (ksp) inhibitors for the treatment of cancer
NO20071926L (no) Anvendelse av en mTOR-inhibitor i behandling av uterint leioyom.
NO20050427L (no) Carvedilolfosfatsalter og/eller solvater derav, tilsvarende preparater og/eller behandlingsfremgangsmater
NO20073396L (no) Farmasoytiske kombinasjoner av en angiotensinreceptorantagonist og en NEP-inhibitor
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
NO20065260L (no) Tri(cyklo)substituerte amidforbindelser
NO20063368L (no) Alfa-aminoamid-derivater anvendelige ved behandling av lidelser i nedre urinveier
NO20072355L (no) Cupredoxinderiverte transportmidler og metoder for fremstilling av disse
ATE435015T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
NO20014230L (no) Fremgangsmåter og preparater som anvender (+) norcisaprid i kombinasjon med protonpumpeinhibitorer eller H2reseptorantagonister
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
IS5898A (is) 5HT1 viðtaka gerandefni og metóklópramíð til meðhöndlunar á mígreni
DE60315270D1 (de) Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
ATE418336T1 (de) Verwendung von i kappa b-kinase inhibitoren in der schmerztherapie
MXPA04006572A (es) Terapia de combinacion antivirica.
EP1534278A4 (en) NITROSED PROTONATE PUMP INHIBITORS, COMPOSITIONS AND USE METHOD
EA200970875A1 (ru) Производные индолизинуксусной кислоты в качестве антагонистов crth2

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application